The pharmaceuticals industry is set for a surge in deal-making this year, as companies under pressure from weak drugs pricing and higher costs take advantage of low valuations and a tax-friendly political climate in the US to bolster faltering sales growth....
WWW.TELEGRAPH.CO.UK
READ MORE
|
Canadian physicians are being advised to reduce their prescribing of opioid medication to patients with chronic non-cancer pain in a new guideline for clinical care that focuses on harm reduction....
READ MORE
|
AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of the gut microbiome in order to increase the efficacy of cancer immunotherapy. The tie-up is based on preclinical and clinical evidence suggesting that the composition of the gastrointestinal microbiome affects the clinical response to checkpoint inhibitor immunotherapy. Evidence supports the hypothesis that modification of the microbiome may improve clini...
READ MORE
|
Robocath, based in Rouen, France, landed European regulatory approval to introduce its R-One robotic catheterization system. The R-One provides interventional cardiologists a way to precisely advance and manipulates catheter-based tools while remaining apart from patients and not exposed to dangerous X-rays. The company believes that the system can improve certain procedures by providing a reliable and accurate use of instruments, without depending on the physician’s ability to provide the...
READ MORE
|
Indian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake in start-up Wellthy Therapeutics. Under the terms of their agreement Wellthy and Cipla – which is India’s third-biggest pharma company – will work together on combined drug and digital therapies for type 2 diabetes as well as for patients with cardiovascular disease. Cipla is paying around 105 million rupees ($1.5 million) for its stake in Wellthy. The aim is to offer &...
READ MORE
|
Big data, blockchain, cloud computing and cybersecurity are the main technologies where pharma companies see the need to invest, the latest survey data from GlobalData, a leading data and analytics company, suggests. GlobalData’s latest report, ‘Emerging Technology Trends Survey – Pharma 2019’, reveals that over 70% of pharma executives, who have some level of responsibility with regards to the implementation of new and emerging technologies, prioritize data protection an...
READ MORE
|